Metabolic dysfunction-associated steatotic liver disease (MASLD) occurs in subjects with obesity and metabolic syndrome. MASLD may progress from simple steatosis (i.e., hepatic steatosis) to steatohepatitis, characterized by inflammatory changes and liver cell damage, substantially increasing mortality. Lifestyle measures associated with weight loss and/or appropriate diet help reduce liver fat accumulation, thereby potentially limiting progression to steatohepatitis. As for diet, both total energy and macronutrient composition significantly influence the liver's fat content. For example, the type of dietary fatty acids can affect the metabolism of lipids and hence their tissue accumulation, with saturated fatty acids having a greater ability to promote fat storage in the liver than polyunsaturated ones. In particular, polyunsaturated fatty acids of n-3 series (omega-3), such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), have been intensively studied for their antisteatotic effects, both in preclinical animal models of obesity and hepatic steatosis and in overweight/obese patients. Their effects may depend not only on the dose and duration of administration of omega-3, or DHA/EPA ratio, but also on the lipid class used for their supplementation. This review summarizes the available evidence from recent comparative studies using omega-3 supplementation via different lipid classes. Albeit the evidence is mainly limited to preclinical studies, it suggests that phospholipids and possibly wax esters could provide greater efficacy against MASLD compared to traditional chemical forms of omega-3 supplementation (i.e., triacylglycerols, ethyl esters). This cannot be attributed solely to improved EPA and/or DHA bioavailability, but other mechanisms may be involved. Keywords: MASLD • Metabolic dysfunction-associated steatotic liver disease • NAFLD • Non-alcoholic fatty liver disease • n-3 polyunsaturated fatty acids.

Laboratory of Adipose Tissue Biology Institute of Physiology of the Czech Academy of Sciences Prague Czech Republic

Zobrazit více v PubMed

Younossi Z, Tacke F, Arrese M, Chander Sharma B, Mostafa I, Bugianesi E, Wai-Sun Wong V, Yilmaz Y, George J, Fan J, Vos MB. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69:2672–2682. doi: 10.1002/hep.30251. PubMed DOI

Eslam M, Sanyal AJ, George J International Consensus P. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158:1999–2014 e1991. doi: 10.1053/j.gastro.2019.11.312. PubMed DOI

Gofton C, Upendran Y, Zheng MH, George J. MAFLD: How is it different from NAFLD? Clin Mol Hepatol. 2023;29:S17–S31. doi: 10.3350/cmh.2022.0367. PubMed DOI PMC

Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, Arrese M, Bataller R, Beuers U, Boursier J, Bugianesi E, Byrne CD, Castro Narro GE, Chowdhury A, Cortez-Pinto H, Cryer DR, Cusi K, El-Kassas M, Klein S, Eskridge W, Fan J, Gawrieh S, Guy CD, Harrison SA, Kim SU, Koot BG, Korenjak M, Kowdley KV, Lacaille F, Loomba R, Mitchell-Thain R, Morgan TR, Powell EE, Roden M, Romero-Gomez M, Silva M, Singh SP, Sookoian SC, Spearman CW, Tiniakos D, Valenti L, Vos MB, Wong VW, Xanthakos S, Yilmaz Y, Younossi Z, Hobbs A, Villota-Rivas M, Newsome PN group NNc. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023 doi: 10.1097/HEP.0000000000000520. PubMed DOI

Simon TG, Roelstraete B, Khalili H, Hagstrom H, Ludvigsson JF. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut. 2021;70:1375–1382. doi: 10.1136/gutjnl-2020-322786. PubMed DOI PMC

Puengel T, Tacke F. Efruxifermin, an investigational treatment for fibrotic or cirrhotic nonalcoholic steatohepatitis (NASH) Expert Opin Investig Drugs. 2023;32:451–461. doi: 10.1080/13543784.2023.2230115. PubMed DOI

Francque SM, Bedossa P, Ratziu V, Anstee QM, Bugianesi E, Sanyal AJ, Loomba R, Harrison SA, Balabanska R, Mateva L, Lanthier N, Alkhouri N, Moreno C, Schattenberg JM, Stefanova-Petrova D, Vonghia L, Rouzier R, Guillaume M, Hodge A, Romero-Gomez M, Huot-Marchand P, Baudin M, Richard MP, Abitbol JL, Broqua P, Junien JL, Abdelmalek MF, Group NS. A randomized, controlled trial of the Pan-PPAR agonist lanifibranor in NASH. N Engl J Med. 2021;385:1547–1558. doi: 10.1056/NEJMoa2036205. PubMed DOI

Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, Sanyal AJ, Sejling AS, Harrison SA, Investigators NN. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384:1113–1124. doi: 10.1056/NEJMoa2028395. PubMed DOI

Golabi P, Locklear CT, Austin P, Afdhal S, Byrns M, Gerber L, Younossi ZM. Effectiveness of exercise in hepatic fat mobilization in non-alcoholic fatty liver disease: Systematic review. World J Gastroenterol. 2016;22:6318–6327. doi: 10.3748/wjg.v22.i27.6318. PubMed DOI PMC

Katsagoni CN, Papatheodoridis GV, Ioannidou P, Deutsch M, Alexopoulou A, Papadopoulos N, Papageorgiou MV, Fragopoulou E, Kontogianni MD. Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial. Br J Nutr. 2018;120:164–175. doi: 10.1017/S000711451800137X. PubMed DOI

Hallsworth K, Adams LA. Lifestyle modification in NAFLD/NASH: Facts and figures. JHEP Rep. 2019;1:468–479. doi: 10.1016/j.jhepr.2019.10.008. PubMed DOI PMC

Hodson L, Rosqvist F, Parry SA. The influence of dietary fatty acids on liver fat content and metabolism. Proc Nutr Soc. 2020;79:30–41. doi: 10.1017/S0029665119000569. PubMed DOI

Rosqvist F, Iggman D, Kullberg J, Cedernaes J, Johansson HE, Larsson A, Johansson L, Ahlstrom H, Arner P, Dahlman I, Riserus U. Overfeeding polyunsaturated and saturated fat causes distinct effects on liver and visceral fat accumulation in humans. Diabetes. 2014;63:2356–2368. doi: 10.2337/db13-1622. PubMed DOI

Luukkonen PK, Sadevirta S, Zhou Y, Kayser B, Ali A, Ahonen L, Lallukka S, Pelloux V, Gaggini M, Jian C, Hakkarainen A, Lundbom N, Gylling H, Salonen A, Oresic M, Hyotylainen T, Orho-Melander M, Rissanen A, Gastaldelli A, Clement K, Hodson L, Yki-Jarvinen H. Saturated fat is more metabolically harmful for the human liver than unsaturated fat or simple sugars. Diabetes Care. 2018;41:1732–1739. doi: 10.2337/dc18-0071. PubMed DOI PMC

Bray GA, Krauss RM. Overfeeding of polyunsaturated versus saturated Fatty acids reduces ectopic fat. Diabetes. 2014;63:2222–2224. doi: 10.2337/db14-0493. PubMed DOI PMC

Roche HM, Gibney MJ. Effect of long-chain n-3 polyunsaturated fatty acids on fasting and postprandial triacylglycerol metabolism1. Am J Clin Nutr. 2000;71:232S–237. doi: 10.1093/ajcn/71.1.232S. PubMed DOI

Schuchardt JP, Neubronner J, Kressel G, Merkel M, von SC, Hahn A. Moderate doses of EPA and DHA from re-esterified triacylglycerols but not from ethyl-esters lower fasting serum triacylglycerols in statin-treated dyslipidemic subjects: Results from a six month randomized controlled trial. Prostaglandins Leukot Essent Fatty Acids. 2011;85:381–386. doi: 10.1016/j.plefa.2011.07.006. PubMed DOI

Veleba J, Kopecky J, Jr, Janovska P, Kuda O, Horakova O, Malinska H, Kazdova L, Oliyarnyk O, Skop V, Trnovska J, Hajek M, Skoch A, Flachs P, Bardova K, Rossmeisl M, Olza J, de Castro GS, Calder PC, Gardlo A, Fiserova E, Jensen J, Bryhn M, Kopecky J, Sr, Pelikanova T. Combined intervention with pioglitazone and −3 fatty acids in metformin-treated type 2 diabetic patients: improvement of lipid metabolism. Nutr Metab (Lond) 2015;12:52. doi: 10.1186/s12986-015-0047-9. PubMed DOI PMC

Pavlisova J, Bardova K, Stankova B, Tvrzicka E, Kopecky J, Rossmeisl M. Corn oil versus lard: Metabolic effects of omega-3 fatty acids in mice fed obesogenic diets with different fatty acid composition. Biochimie. 2016;124:150–162. doi: 10.1016/j.biochi.2015.07.001. PubMed DOI

Green CJ, Pramfalk C, Charlton CA, Gunn PJ, Cornfield T, Pavlides M, Karpe F, Hodson L. Hepatic de novo lipogenesis is suppressed and fat oxidation is increased by omega-3 fatty acids at the expense of glucose metabolism. BMJ Open Diabetes Res Care. 2020:8. doi: 10.1136/bmjdrc-2019-000871. PubMed DOI PMC

Flachs P, Rossmeisl M, Bryhn M, Kopecky J. Cellular and molecular effects of n-3 polyunsaturated fatty acids on adipose tissue biology and metabolism. Clin Sci (Lond) 2009;116:1–16. doi: 10.1042/CS20070456. PubMed DOI

Glass CK, Olefsky JM. Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab. 2012;15:635–645. doi: 10.1016/j.cmet.2012.04.001. PubMed DOI PMC

Calder PC. Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance. Biochim Biophys Acta. 2015;1851:469–484. doi: 10.1016/j.bbalip.2014.08.010. PubMed DOI

de Castro GS, Calder PC. Non-alcoholic fatty liver disease and its treatment with n-3 polyunsaturated fatty acids. Clin Nutr. 2018;37:37–55. doi: 10.1016/j.clnu.2017.01.006. PubMed DOI

Spooner MH, Jump DB. Omega-3 fatty acids and nonalcoholic fatty liver disease in adults and children: where do we stand? Curr Opin Clin Nutr Metab Care. 2019;22:103–110. doi: 10.1097/MCO.0000000000000539. PubMed DOI PMC

Lee CH, Fu Y, Yang SJ, Chi CC. Effects of Omega-3 polyunsaturated fatty acid supplementation on non-alcoholic fatty liver: a systematic review and meta-analysis. Nutrients. 2020:12. doi: 10.3390/nu12092769. PubMed DOI PMC

Argo CK, Patrie JT, Lackner C, Henry TD, de Lange EE, Weltman AL, Shah NL, Al-Osaimi AM, Pramoonjago P, Jayakumar S, Binder LP, Simmons-Egolf WD, Burks SG, Bao Y, Taylor AG, Rodriguez J, Caldwell SH. Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. J Hepatol. 2015;62:190–197. doi: 10.1016/j.jhep.2014.08.036. PubMed DOI PMC

Caldwell S. NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs. Clin Mol Hepatol. 2017;23:103–108. doi: 10.3350/cmh.2017.0103. PubMed DOI PMC

Musa-Veloso K, Venditti C, Lee HY, Darch M, Floyd S, West S, Simon R. Systematic review and meta-analysis of controlled intervention studies on the effectiveness of long-chain omega-3 fatty acids in patients with nonalcoholic fatty liver disease. Nutr Rev. 2018;76:581–602. doi: 10.1093/nutrit/nuy022. PubMed DOI PMC

Scorletti E, Byrne CD. Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action. Mol Aspects Med. 2018;64:135–146. doi: 10.1016/j.mam.2018.03.001. PubMed DOI

Mitrovic M, Sistilli G, Horakova O, Rossmeisl M. Omega-3 phospholipids and obesity-associated NAFLD: Potential mechanisms and therapeutic perspectives. Eur J Clin Invest. 2022;52:e13650. doi: 10.1111/eci.13650. PubMed DOI

Schots PC, Pedersen AM, Eilertsen KE, Olsen RL, Larsen TS. Possible health effects of a wax ester rich marine oil. Front Pharmacol. 2020;11:961. doi: 10.3389/fphar.2020.00961. PubMed DOI PMC

Ruzickova J, Rossmeisl M, Prazak T, Flachs P, Sponarova J, Vecka M, Tvrzicka E, Bryhn M, Kopecky J. Omega-3 PUFA of marine origin limit diet-induced obesity in mice by reducing cellularity of adipose tissue. Lipids. 2004;39:1177–1185. doi: 10.1007/s11745-004-1345-9. PubMed DOI

Schuchardt JP, Hahn A. Bioavailability of long-chain omega-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids. 2013;89:1–8. doi: 10.1016/j.plefa.2013.03.010. PubMed DOI

Paluchova V, Vik A, Cajka T, Brezinova M, Brejchova K, Bugajev V, Draberova L, Draber P, Buresova J, Kroupova P, Bardova K, Rossmeisl M, Kopecky J, Hansen TV, Kuda O. Triacylglycerol-rich oils of marine origin are optimal nutrients for induction of polyunsaturated docosahexaenoic acid ester of hydroxy linoleic acid (13-DHAHLA) with anti-inflammatory properties in mice. Mol Nutr Food Res. 2020;64:e1901238. doi: 10.1002/mnfr.201901238. PubMed DOI

Rossmeisl M, Jilkova ZM, Kuda O, Jelenik T, Medrikova D, Stankova B, Kristinsson B, Haraldsson GG, Svensen H, Stoknes I, Sjovall P, Magnusson Y, Balvers MG, Verhoeckx KC, Tvrzicka E, Bryhn M, Kopecky J. Metabolic effects of n-3 PUFA as phospholipids are superior to triglycerides in mice fed a high-fat diet: possible role of endocannabinoids. PLoS One. 2012;7:e38834. doi: 10.1371/journal.pone.0038834. PubMed DOI PMC

Rossmeisl M, Pavlisova J, Bardova K, Kalendova V, Buresova J, Kuda O, Kroupova P, Stankova B, Tvrzicka E, Fiserova E, Horakova O, Kopecky J. Increased plasma levels of palmitoleic acid may contribute to beneficial effects of Krill oil on glucose homeostasis in dietary obese mice. Biochim Biophys Acta Mol Cell Biol Lipids. 2020:158732. doi: 10.1016/j.bbalip.2020.158732. PubMed DOI

Sistilli G, Kalendova V, Cajka T, Irodenko I, Bardova K, Oseeva M, Zacek P, Kroupova P, Horakova O, Lackner K, Gastaldelli A, Kuda O, Kopecky J, Rossmeisl M. Krill Oil Supplementation Reduces Exacerbated Hepatic Steatosis Induced by Thermoneutral Housing in Mice with Diet-Induced Obesity. Nutrients. 2021:13. doi: 10.3390/nu13020437. PubMed DOI PMC

Sugimoto K, Hosomi R, Yoshida M, Fukunaga K. Effects of dietary oils prepared from the internal organs of the Japanese giant scallop (Patinopecten yessoensis) on cholesterol metabolism in obese type-II diabetic KK-A(y) mice. Food Sci Nutr. 2020;8:6727–6737. doi: 10.1002/fsn3.1967. PubMed DOI PMC

Chen YF, Fan ZK, Gao X, Zhou F, Guo XF, Sinclair AJ, Li D. n-3 polyunsaturated fatty acids in phospholipid or triacylglycerol form attenuate nonalcoholic fatty liver disease via mediating cannabinoid receptor 1/adiponectin/ceramide pathway. J Nutr Biochem. 2024;123:109484. doi: 10.1016/j.jnutbio.2023.109484. PubMed DOI

Wang Q, Wang R, Zhao X, Lu H, Zhang P, Dong X, Wang Y. Comparison of the effect of phospholipid extracts from salmon and silver carp heads on high-fat-diet-induced metabolic syndrome in C57BL/6J Mice. Mar Drugs. 2023:21. doi: 10.3390/md21070409. PubMed DOI PMC

Aydin Cil M, Ghosi Ghareaghaji A, Bayir Y, Buyuktuncer Z, Besler HT. Efficacy of krill oil versus fish oil on obesity-related parameters and lipid gene expression in rats: randomized controlled study. PeerJ. 2021;9:e12009. doi: 10.7717/peerj.12009. PubMed DOI PMC

Botelho PB, da Mariano KR, Rogero MM, de Castro IA. Effect of Echium oil compared with marine oils on lipid profile and inhibition of hepatic steatosis in LDLr knockout mice. Lipids Health Dis. 2013;12:38. doi: 10.1186/1476-511X-12-38. PubMed DOI PMC

Gui L, Chen S, Wang H, Ruan M, Liu Y, Li N, Zhang H, Liu Z. omega-3 PUFAs alleviate high-fat diet-induced circadian intestinal microbes dysbiosis. Mol Nutr Food Res. 2019;63:e1900492. doi: 10.1002/mnfr.201900492. PubMed DOI

Tang X, Li ZJ, Xu J, Xue Y, Li JZ, Wang JF, Yanagita T, Xue CH, Wang YM. Short term effects of different omega-3 fatty acid formulation on lipid metabolism in mice fed high or low fat diet. Lipids Health Dis. 2012;11:70. doi: 10.1186/1476-511X-11-70. PubMed DOI PMC

Hoper AC, Salma W, Sollie SJ, Hafstad AD, Lund J, Khalid AM, Raa J, Aasum E, Larsen TS. Wax esters from the marine copepod Calanus finmarchicus reduce diet-induced obesity and obesity-related metabolic disorders in mice. J Nutr. 2014;144:164–169. doi: 10.3945/jn.113.182501. PubMed DOI

Ferramosca A, Conte L, Zara V. A krill oil supplemented diet reduces the activities of the mitochondrial tricarboxylate carrier and of the cytosolic lipogenic enzymes in rats. J Anim Physiol Anim Nutr (Berl) 2012;96:295–306. doi: 10.1111/j.1439-0396.2011.01135.x. PubMed DOI

Tillander V, Bjorndal B, Burri L, Bohov P, Skorve J, Berge RK, Alexson SE. Fish oil and krill oil supplementations differentially regulate lipid catabolic and synthetic pathways in mice. Nutr Metab (Lond) 2014;11:20. doi: 10.1186/1743-7075-11-20. PubMed DOI PMC

Skorve J, Hilvo M, Vihervaara T, Burri L, Bohov P, Tillander V, Bjorndal B, Suoniemi M, Laaksonen R, Ekroos K, Berge RK, Alexson SE. Fish oil and krill oil differentially modify the liver and brain lipidome when fed to mice. Lipids Health Dis. 2015;14:88. doi: 10.1186/s12944-015-0086-2. PubMed DOI PMC

Yook JS, Kim KA, Park JE, Lee SH, Cha YS. Microalgal oil supplementation has an anti-obesity effect in C57BL/6J mice fed a high fat diet. Prev Nutr Food Sci. 2015;20:230–237. doi: 10.3746/pnf.2015.20.4.230. PubMed DOI PMC

Yu J, Ma Y, Sun J, Ran L, Li Y, Wang N, Yu T, Gao W, Jia W, Jiang R, Guo M, Bi Y, Wu Y. Microalgal oil from schizochytrium sp. prevents HFD-induced abdominal fat accumulation in mice. J Am Coll Nutr. 2017;36:347–356. doi: 10.1080/07315724.2017.1302366. PubMed DOI

Shang T, Liu L, Zhou J, Zhang M, Hu Q, Fang M, Wu Y, Yao P, Gong Z. Protective effects of various ratios of DHA/EPA supplementation on high-fat diet-induced liver damage in mice. Lipids Health Dis. 2017;16:65. doi: 10.1186/s12944-017-0461-2. PubMed DOI PMC

Sugimoto K, Hosomi R, Yoshida M, Fukunaga K. Dietary phospholipids prepared from scallop internal organs attenuate the serum and liver cholesterol contents by enhancing the expression of cholesterol hydroxylase in the liver of mice. Front Nutr. 2021;8:761928. doi: 10.3389/fnut.2021.761928. PubMed DOI PMC

Ran L, Yu J, Ma R, Yao Q, Wang M, Bi Y, Yu Z, Wu Y. Microalgae oil from Schizochytrium sp. alleviates obesity and modulates gut microbiota in high-fat diet-fed mice. Food Funct. 2022;13:12799–12813. doi: 10.1039/D2FO01772E. PubMed DOI

Kroupova P, van Schothorst EM, Keijer J, Bunschoten A, Vodicka M, Irodenko I, Oseeva M, Zacek P, Kopecky J, Rossmeisl M, Horakova O. Omega-3 phospholipids from krill oil enhance intestinal fatty acid oxidation more effectively than omega-3 triacylglycerols in high-fat diet-fed obese mice. Nutrients. 2020:12. doi: 10.3390/nu12072037. PubMed DOI PMC

Sugimoto K, Hosomi R, Shimono T, Kanda S, Nishiyama T, Yoshida M, Fukunaga K. Comparison of the Cholesterol-Lowering Effect of Scallop Oil Prepared from the Internal Organs of the Japanese Giant Scallop (Patinopecten yessoensis), Fish Oil, and Krill Oil in Obese Type II Diabetic KK-A (y) Mice. J Oleo Sci. 2021;70:965–977. doi: 10.5650/jos.ess21032. PubMed DOI

Cui C, Li Y, Gao H, Zhang H, Han J, Zhang D, Li Y, Zhou J, Lu C, Su X. Modulation of the gut microbiota by the mixture of fish oil and krill oil in high-fat diet-induced obesity mice. PLoS One. 2017;12:e0186216. doi: 10.1371/journal.pone.0186216. PubMed DOI PMC

Hosomi R, Fukunaga K, Nagao T, Tanizaki T, Miyauchi K, Yoshida M, Kanda S, Nishiyama T, Takahashi K. Effect of dietary partial hydrolysate of phospholipids, rich in docosahexaenoic acid-bound lysophospholipids, on lipid and fatty acid composition in rat serum and liver. J Food Sci. 2019;84:183–191. doi: 10.1111/1750-3841.14416. PubMed DOI

Tou JC, Altman SN, Gigliotti JC, Benedito VA, Cordonier EL. Different sources of omega-3 polyunsaturated fatty acids affects apparent digestibility, tissue deposition, and tissue oxidative stability in growing female rats. Lipids Health Dis. 2011;10:179. doi: 10.1186/1476-511X-10-179. PubMed DOI PMC

Maki KC, Yurko-Mauro K, Dicklin MR, Schild AL, Geohas JG. A new, microalgal DHA- and EPA- containing oil lowers triacylglycerols in adults with mild-to-moderate hypertriglyceridemia. Prostaglandins Leukot Essent Fatty Acids. 2014;91:141–148. doi: 10.1016/j.plefa.2014.07.012. PubMed DOI

Cook CM, Hallaraker H, Saebo PC, Innis SM, Kelley KM, Sanoshy KD, Berger A, Maki KC. Bioavailability of long chain omega-3 polyunsaturated fatty acids from phospholipid-rich herring roe oil in men and women with mildly elevated triacylglycerols. Prostaglandins Leukot Essent Fatty Acids. 2016;111:17–24. doi: 10.1016/j.plefa.2016.01.007. PubMed DOI

Hedengran A, Szecsi PB, Dyerberg J, Harris WS, Stender S. n-3 PUFA esterified to glycerol or as ethyl esters reduce non-fasting plasma triacylglycerol in subjects with hypertriglyceridemia: a randomized trial. Lipids. 2015;50:165–175. doi: 10.1007/s11745-014-3968-6. PubMed DOI

Schuchardt JP, Neubronner J, Block RC, von Schacky C, Hahn A. Associations between Omega-3 Index increase and triacylglyceride decrease in subjects with hypertriglyceridemia in response to six month of EPA and DHA supplementation. Prostaglandins Leukot Essent Fatty Acids. 2014;91:129–134. doi: 10.1016/j.plefa.2014.07.014. PubMed DOI

Meyer BJ, Lane AE, Mann NJ. Comparison of seal oil to tuna oil on plasma lipid levels and blood pressure in hypertriglyceridaemic subjects. Lipids. 2009;44:827–835. doi: 10.1007/s11745-009-3333-3. PubMed DOI

Kopecky J, Rossmeisl M, Flachs P, Kuda O, Brauner P, Jilkova Z, Stankova B, Tvrzicka E, Bryhn M. n-3 PUFA: bioavailability and modulation of adipose tissue function. Proc Nutr Soc. 2009;68:361–369. doi: 10.1017/S0029665109990231. PubMed DOI

Neubronner J, Schuchardt JP, Kressel G, Merkel M, von SC, Hahn A. Enhanced increase of omega-3 index in response to long-term n-3 fatty acid supplementation from triacylglycerides versus ethyl esters. Eur J ClinNutr. 2011;65:247–254. doi: 10.1038/ejcn.2010.239. PubMed DOI

Pedersen AM, Salma W, Hoper AC, Larsen TS, Olsen RL. Lipid profile of mice fed a high-fat diet supplemented with a wax ester-rich marine oil. Eur J Lipid Sci Tech. 2014;116:1718–1726. doi: 10.1002/ejlt.201400052. DOI

Ulven SM, Kirkhus B, Lamglait A, Basu S, Elind E, Haider T, Berge K, Vik H, Pedersen JI. Metabolic effects of krill oil are essentially similar to those of fish oil but at lower dose of EPA and DHA, in healthy volunteers. Lipids. 2011;46:37–46. doi: 10.1007/s11745-010-3490-4. PubMed DOI PMC

Schuchardt JP, Schneider I, Meyer H, Neubronner J, von Schacky C, Hahn A. Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations - a comparative bioavailability study of fish oil vs. krill oil. Lipids Health Dis. 2011;10:145. doi: 10.1186/1476-511X-10-145. PubMed DOI PMC

Maki KC, Reeves MS, Farmer M, Griinari M, Berge K, Vik H, Hubacher R, Rains TM. Krill oil supplementation increases plasma concentrations of eicosapentaenoic and docosahexaenoic acids in overweight and obese men and women. Nutr Res. 2009;29:609–615. doi: 10.1016/j.nutres.2009.09.004. PubMed DOI

Vosskotter F, Burhop M, Hahn A, Schuchardt JP. Equal bioavailability of omega-3 PUFA from Calanus oil, fish oil and krill oil: A 12-week randomized parallel study. Lipids. 2023;58:129–138. doi: 10.1002/lipd.12369. PubMed DOI

Cook CM, Larsen TS, Derrig LD, Kelly KM, Tande KS. Wax Ester Rich Oil From The Marine Crustacean, Calanus finmarchicus, is a Bioavailable Source of EPA and DHA for Human Consumption. Lipids. 2016;51:1137–1144. doi: 10.1007/s11745-016-4189-y. PubMed DOI

Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115:1343–1351. doi: 10.1172/JCI23621. PubMed DOI PMC

Schweiger M, Romauch M, Schreiber R, Grabner GF, Hutter S, Kotzbeck P, Benedikt P, Eichmann TO, Yamada S, Knittelfelder O, Diwoky C, Doler C, Mayer N, De Cecco W, Breinbauer R, Zimmermann R, Zechner R. Pharmacological inhibition of adipose triglyceride lipase corrects high-fat diet-induced insulin resistance and hepatosteatosis in mice. Nat Comm. 2017;8:14859. https://doi.org/10.1038/ncomms14859, https://doi.org/10.1038/ncomms15490. PubMed DOI PMC

Einer C, Hohenester S, Wimmer R, Wottke L, Artmann R, Schulz S, Gosmann C, Simmons A, Leitzinger C, Eberhagen C, Borchard S, Schmitt S, Hauck SM, von Toerne C, Jastroch M, Walheim E, Rust C, Gerbes AL, Popper B, Mayr D, Schnurr M, Vollmar AM, Denk G, Zischka H. Mitochondrial adaptation in steatotic mice. Mitochondrion. 2018;40:1–12. doi: 10.1016/j.mito.2017.08.015. PubMed DOI

Dewidar B, Mastrototaro L, Englisch C, Ress C, Granata C, Rohbeck E, Pesta D, Heilmann G, Wolkersdorfer M, Esposito I, Reina Do Fundo M, Zivehe F, Yavas A, Roden M. Alterations of hepatic energy metabolism in murine models of obesity, diabetes and fatty liver diseases. EBio Med. 2023;94:104714. doi: 10.1016/j.ebiom.2023.104714. PubMed DOI PMC

Kammoun HL, Chabanon H, Hainault I, Luquet S, Magnan C, Koike T, Ferre P, Foufelle F. GRP78 expression inhibits insulin and ER stress-induced SREBP-1c activation and reduces hepatic steatosis in mice. J Clin Invest. 2009;119:1201–1215. doi: 10.1172/JCI37007. PubMed DOI PMC

Osei-Hyiaman D, Liu J, Zhou L, Godlewski G, Harvey-White J, Jeong WI, Batkai S, Marsicano G, Lutz B, Buettner C, Kunos G. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest. 2008;118:3160–3169. doi: 10.1172/JCI34827. PubMed DOI PMC

Ramos VM, Kowaltowski AJ, Kakimoto PA. Autophagy in hepatic steatosis: a structured review. Front Cell Dev Biol. 2021;9:657389. doi: 10.3389/fcell.2021.657389. PubMed DOI PMC

Sharma L, Lone NA, Knott RM, Hassan A, Abdullah T. Trigonelline prevents high cholesterol and high fat diet induced hepatic lipid accumulation and lipo-toxicity in C57BL/6J mice, via restoration of hepatic autophagy. Food Chem Toxicol. 2018;121:283–296. doi: 10.1016/j.fct.2018.09.011. PubMed DOI

Simoes ICM, Amorim R, Teixeira J, Karkucinska-Wieckowska A, Carvalho A, Pereira SP, Simoes RF, Szymanska S, Dabrowski M, Janikiewicz J, Dobrzyn A, Oliveira PJ, Potes Y, Wieckowski MR. The alterations of mitochondrial function during NAFLD progression-an independent effect of mitochondrial ROS production. Int J Mol Sci. 2021:22. doi: 10.3390/ijms22136848. PubMed DOI PMC

Vasko R, Goligorsky MS. Dysfunctional lysosomal autophagy leads to peroxisomal oxidative burnout and damage during endotoxin-induced stress. Autophagy. 2013;9:442–444. doi: 10.4161/auto.23344. PubMed DOI PMC

Ding L, Sun W, Balaz M, He A, Klug M, Wieland S, Caiazzo R, Raverdy V, Pattou F, Lefebvre P, Lodhi IJ, Staels B, Heim M, Wolfrum C. Peroxisomal beta-oxidation acts as a sensor for intracellular fatty acids and regulates lipolysis. Nat Metab. 2021;3:1648–1661. doi: 10.1038/s42255-021-00489-2. PubMed DOI PMC

Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, Burcelin R. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008;57:1470–1481. doi: 10.2337/db07-1403. PubMed DOI

Winer DA, Winer S, Dranse HJ, Lam TK. Immunologic impact of the intestine in metabolic disease. J Clin Invest. 2017;127:33–42. doi: 10.1172/JCI88879. PubMed DOI PMC

Delgado TC, de Las Heras J, Martinez-Chantar ML. Understanding gut-liver axis nitrogen metabolism in Fatty Liver Disease. Front Endocrinol (Lausanne) 2022;13:1058101. doi: 10.3389/fendo.2022.1058101. PubMed DOI PMC

Jump DB, Lytle KA, Depner CM, Tripathy S. Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease. Pharmacol Ther. 2018;181:108–125. doi: 10.1016/j.pharmthera.2017.07.007. PubMed DOI PMC

Scorletti E, Bhatia L, McCormick KG, Clough GF, Nash K, Hodson L, Moyses HE, Calder PC, Byrne CD, Study W. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study. Hepatology. 2014;60:1211–1221. doi: 10.1002/hep.27289. PubMed DOI

Smid V, Dvorak K, Sedivy P, Kosek V, Lenicek M, Dezortova M, Hajslova J, Hajek M, Vitek L, Bechynska K, Bruha R. Effect of Omega-3 Polyunsaturated Fatty Acids on Lipid Metabolism in Patients With Metabolic Syndrome and NAFLD. Hepatol Commun. 2022;6:1336–1349. doi: 10.1002/hep4.1906. PubMed DOI PMC

Du ZY, Ma T, Liaset B, Keenan AH, Araujo P, Lock EJ, Demizieux L, Degrace P, Froyland L, Kristiansen K, Madsen L. Dietary eicosapentaenoic acid supplementation accentuates hepatic triglyceride accumulation in mice with impaired fatty acid oxidation capacity. Biochim Biophys Acta. 2013;1831:291–299. doi: 10.1016/j.bbalip.2012.10.002. PubMed DOI

Lopez-Vicario C, Sebastian D, Casulleras M, Duran-Guell M, Flores-Costa R, Aguilar F, Lozano JJ, Zhang IW, Titos E, Kang JX, Zorzano A, Arita M, Claria J. Essential lipid autacoids rewire mitochondrial energy efficiency in metabolic dysfunction-associated fatty liver disease. Hepatology. 2023;77:1303–1318. doi: 10.1002/hep.32647. PubMed DOI

Flachs P, Ruhl R, Hensler M, Janovska P, Zouhar P, Kus V, Macek JZ, Papp E, Kuda O, Svobodova M, Rossmeisl M, Tsenov G, Mohamed-Ali V, Kopecky J. Synergistic induction of lipid catabolism and anti-inflammatory lipids in white fat of dietary obese mice in response to calorie restriction and n-3 fatty acids. Diabetologia. 2011;54:2626–2638. doi: 10.1007/s00125-011-2233-2. PubMed DOI

Fiamoncini J, Turner N, Hirabara SM, Salgado TM, Marcal AC, Leslie S, da Silva SM, Deschamps FC, Luz J, Cooney GJ, Curi R. Enhanced peroxisomal beta-oxidation is associated with prevention of obesity and glucose intolerance by fish oil-enriched diets. Obesity. 2013;21:1200–1207. doi: 10.1002/oby.20132. PubMed DOI

Ferramosca A, Conte A, Burri L, Berge K, De NF, Giudetti AM, Zara V. A krill oil supplemented diet suppresses hepatic steatosis in high-fat fed rats. Plos One. 2012;7:e38797. doi: 10.1371/journal.pone.0038797. PubMed DOI PMC

Rossmeisl M, Medrikova D, van Schothorst EM, Pavlisova J, Kuda O, Hensler M, Bardova K, Flachs P, Stankova B, Vecka M, Tvrzicka E, Zak A, Keijer J, Kopecky J. Omega-3 phospholipids from fish suppress hepatic steatosis by integrated inhibition of biosynthetic pathways in dietary obese mice. Biochim Biophys Acta. 2014;1841:267–278. doi: 10.1016/j.bbalip.2013.11.010. PubMed DOI

Lopez-Vicario C, Alcaraz-Quiles J, Garcia-Alonso V, Rius B, Hwang SH, Titos E, Lopategi A, Hammock BD, Arroyo V, Claria J. Inhibition of soluble epoxide hydrolase modulates inflammation and autophagy in obese adipose tissue and liver: role for omega-3 epoxides. Proc Natl Acad Sci U S A. 2015;112:536–541. doi: 10.1073/pnas.1422590112. PubMed DOI PMC

Neschen S, Morino K, Rossbacher JC, Pongratz RL, Cline GW, Sono S, Gillum M, Shulman GI. Fish oil regulates adiponectin secretion by a peroxisome proliferator-activated receptor-gamma-dependent mechanism in mice. Diabetes. 2006;55:924–928. doi: 10.2337/diabetes.55.04.06.db05-0985. PubMed DOI

Flachs P, Mohamed-Ali V, Horakova O, Rossmeisl M, Hosseinzadeh-Attar MJ, Hensler M, Ruzickova J, Kopecky J. Polyunsaturated fatty acids of marine origin induce adiponectin in mice fed high-fat diet. Diabetologia. 2006;49:394–397. doi: 10.1007/s00125-005-0053-y. PubMed DOI

Jelenik T, Rossmeisl M, Kuda O, Jilkova ZM, Medrikova D, Kus V, Hensler M, Janovska P, Miksik I, Baranowski M, Gorski J, Hebrard S, Jensen TE, Flachs P, Hawley S, Viollet B, Kopecky J. AMP-activated protein kinase {alpha}2 subunit is required for the preservation of hepatic insulin sensitivity by n-3 polyunsaturated fatty acids. Diabetes. 2010;59:2737–2746. doi: 10.2337/db09-1716. PubMed DOI PMC

Kuda O, Rossmeisl M, Kopecky J. Omega-3 fatty acids and adipose tissue biology. Mol Aspects Med. 2018;64:147–160. doi: 10.1016/j.mam.2018.01.004. PubMed DOI

Kuda O, Brezinova M, Rombaldova M, Slavikova B, Posta M, Beier P, Janovska P, Veleba J, Kopecky J, Jr, Kudova E, Pelikanova T, Kopecky J. Docosahexaenoic acid-derived fatty acid esters of hydroxy fatty acids (FAHFAs) with anti-inflammatory properties. Diabetes. 2016;65:2580–2590. doi: 10.2337/db16-0385. PubMed DOI

Batetta B, Griinari M, Carta G, Murru E, Ligresti A, Cordeddu L, Giordano E, Sanna F, Bisogno T, Uda S, Collu M, Bruheim I, Di Marzo V, Banni S. Endocannabinoids may mediate the ability of (n-3) fatty acids to reduce ectopic fat and inflammatory mediators in obese Zucker rats. J Nutr. 2009;139:1495–1501. doi: 10.3945/jn.109.104844. PubMed DOI

Rossmeisl M, Pavlisova J, Janovska P, Kuda O, Bardova K, Hansikova J, Svobodova M, Oseeva M, Veleba J, Kopecky J, Jr, Zacek P, Fiserova E, Pelikanova T, Kopecky J. Differential modulation of white adipose tissue endocannabinoid levels by n-3 fatty acids in obese mice and type 2 diabetic patients. Biochim Biophys Acta. 2018;1863:712–725. doi: 10.1016/j.bbalip.2018.03.011. PubMed DOI

Tedesco L, Valerio A, Dossena M, Cardile A, Ragni M, Pagano C, Pagotto U, Carruba MO, Vettor R, Nisoli E. Cannabinoid receptor stimulation impairs mitochondrial biogenesis in mouse white adipose tissue, muscle, and liver: the role of eNOS, p38 MAPK, and AMPK pathways. Diabetes. 2010;59:2826–2836. doi: 10.2337/db09-1881. PubMed DOI PMC

Baker EJ, Miles EA, Burdge GC, Yaqoob P, Calder PC. Metabolism and functional effects of plant-derived omega-3 fatty acids in humans. Prog Lipid Res. 2016;64:30–56. doi: 10.1016/j.plipres.2016.07.002. PubMed DOI